Roth Capital Starts Biotie Therapies (BITI) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
JMP Securities Starts Biotie Therapies (BITI) at Market Outperform
July 6, 2015 8:02 AM EDTJMP Securities initiated coverage on Biotie Therapies (NASDAQ: BITI) with a Market Outperform rating and a price target of $32.00.
For an analyst ratings summary and ratings history on Biotie Therapies click here. For more ratings news on Biotie Therapies click here.
Shares of Biotie Therapies closed at $18.39 yesterday.
... MoreStifel Starts Biotie Therapies (BITI) at Buy
July 6, 2015 8:01 AM EDTStifel initiated coverage on Biotie Therapies (NASDAQ: BITI) with a Buy rating and a price target of $30.00.
For an analyst ratings summary and ratings history on Biotie Therapies click here. For more ratings news on Biotie Therapies click here.
Shares of Biotie Therapies closed at $18.39 yesterday.
... MoreUPDATE: RBC Capital Starts Biotie Therapies (BITI) at Outperform
July 6, 2015 8:01 AM EDT(Updated - July 6, 2015 8:29 AM EDT)
RBC Capital initiated coverage on Biotie Therapies (NASDAQ: BITI) with an Outperform rating and a price target of $35. Analyst Simos Simeonidis is bullish on Tozadenant and thinks it could be the first Parkinsons Disease drug approved with a new mechanism in a generation.
"Tozadenant, Biotie's A2A receptor antagonist, is entering a Phase III... More
